All In Biotech

Drug Trial Radar · NCT01143181

Study to Assess Brincidofovir Treatment of Serious Diseases or Conditions Caused by Double-stranded DNA Viruses

A Multicenter, Open-label Study of CMX001 Treatment of Serious Diseases or Conditions Caused by Double-stranded DNA Viruses

Last checked: Nov 19, 2026Latest source record: Aug 12, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

210

Actual

Start

Dec 2010

Primary completion

Dec 2012

Study completion Dec 2012

Sponsor

Lead sponsor
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
Sponsor type
Industry
First posted
Jun 14, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a multicenter, open-label study of oral brincidofovir (BCV) treatment of serious disease or conditions caused by double-stranded DNA (dsDNA) virus(es). Subjects received either a weight-based or a fixed dose of oral BCV once weekly (QW) or twice weekly (BIW) for up to 3 months until clinical disease was resolved or stabilized and/or viral DNA by polymerase chain reaction testing was negative for 4 consecutive weeks, whichever was longer. Under the first protocol amendment, adults and adolescents (≥13 years) received 200 mg or 300 mg BCV BIW (not to exceed 4 mg/kg total weekly dose) depending on the difficulty of treating their disease (i.e., Group 1 or Group 2, respectively), and pediatric subjects (≤12 years) received 4 mg/kg BCV BIW. Under the second protocol amendment, adults and adolescents (≥13 years), regardless of viral infection/disease, had a maximum weekly dose of 200 mg, i.e., 200 mg QW or 100 mg BIW; not to exceed 4mg/kg total weekly dose. Pediatric subjects (≤12 years), regardless of viral infection/disease, had a maximum weekly dose of 4 mg/kg, i.e., 4 mg/kg QW or 2 mg/kg BIW; not to exceed 200 mg.

Conditions

  • Double-stranded DNA Virus

Interventions

  • BrincidofovirDrug

    Brincidofovir (BCV) was administered orally either once or twice weekly for up to 3 months. Treatment may have been extended for an additional 3 months depending a satisfactory review of safety parameters. Subjects could not receive more than a total of 6 months of treatment with BCV without prior approval.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects Who Had a Sustained and Significant Reduction in Plasma Viral Load of Primary dsDNA VirusTime frame: 3 months

Locations

37 sites in 1 country. Site status is shown where the registry gives one.

  • Loma Linda University Hospital

    Loma Linda, California

  • Children's Hospital of LA

    Los Angeles, California

  • UCLA Department of Medicine

    Los Angeles, California

  • CHOC Children's

    Orange, California

  • Univeristy of San Francisco

    San Francisco, California

  • Lucile Packard Children's Hospital

    Stanford, California

  • Children's Hospital of Colorado

    Aurora, Colorado

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • University of Chicago

    Chicago, Illinois

  • University of Iowa

    Iowa City, Iowa

  • Childrens Hospital LSU

    New Orleans, Louisiana

  • NIH

    Bethesda, Maryland

  • Tufts Medical Center

    Boston, Massachusetts

  • Brigham and Womens Hospital

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • University of Minnesota

    Minneapolis, Minnesota

  • St. Louis Children's Hospital

    St Louis, Missouri

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Mt. Sinai

    New York, New York

  • Columbia University

    New York, New York

  • Memorial Sloan Kettering Cancer Institute

    New York, New York

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Levine Children's Hospital Carolina Medical Center

    Charlotte, North Carolina

  • Duke University Medical Center

    Durham, North Carolina

  • Cincinnati Childrens Hospital

    Cincinnati, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • Nationwide Children's Hospital

    Columbus, Ohio

  • Oregon Health and Science University

    Portland, Oregon

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • UPMC

    Pittsburgh, Pennsylvania

  • Childrens Hospital of Pittsburgh

    Pittsburgh, Pennsylvania

  • Cook Children's Medical Center

    Fort Worth, Texas

  • UT MD Anderson Cancer Center

    Houston, Texas

  • Intermountain BMT program LDS Hospital

    Salt Lake City, Utah

  • University of Washington-Fred Hutchinson Cancer Center

    Seattle, Washington

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.